EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer

被引：3

作者：

De Marinis, Filippo ^{[1
]}

Bidoli, Paolo ^{[2
]}

Luciani, Andrea ^{[3
]}

Amoroso, Domenico ^{[4
]}

Tonini, Giuseppe ^{[5
]}

Bertolini, Alessandro ^{[6
]}

Brandes, Alba A. ^{[7
]}

Migliorino, Maria Rita ^{[8
]}

Favaretto, Adolfo ^{[9
]}

Gridelli, Cesare ^{[10
]}

机构：

[1] European Inst Oncol, Div Thorac Oncol, Milan, Italy

[2] San Gerardo Tintori Hosp, Div Med Oncol, Monza, Italy

[3] San Paolo Hosp, Med Oncol, Milan, Italy

[4] Versilia Hosp, Med Oncol Unit, Camaiore, Italy

[5] Campus Biomed Univ Hosp, Med Oncol Unit, Rome, Italy

[6] Hosp Sondrio, Med Oncol Unit, Sondrio, Italy

[7] AUSL IRCCS Inst Neurol Sci, Dept Med Oncol, Bologna, Italy

[8] San Camillo Hosp, Unit Thorac Oncol, Rome, Italy

[9] Ca Foncello Hosp, Unit Oncol, Treviso, Italy

[10] San Giuseppe Moscati Hosp, Div Med Oncol, Avellino, Italy

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 05期

关键词：

Non-squamous non-small-cell lung cancer; elderly; bevacizumab; gemcitabine; cisplatin; CARBOPLATIN; PACLITAXEL; THERAPY; GEMCITABINE;

D O I：

10.21873/anticanres.11586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The management of elderly patients with advanced non-squamous NSCLC includes several strategies. Patients and Methods: Patients (>= 70 years) were randomly assigned to bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m(2) i.v. on days 1-8) (arm A) or bevacizumab (7.5 mg/kg i.v.) and cisplatin (60 mg/m(2) i.v.) plus gemcitabine (1,000 mg/m(2) i.v. on days 1-8) (arm B), to independently evaluate treatments. The primary endpoint was progression-free rate at 6 months; secondary endpoints included progression-free survival (PFS) and safety profiles. Results: At 6 months, 5 (11.6%) patients in arm A and 5 patients (12.5%) in arm B were found to be progression-free. Median PFS was 4.8 months in arm A and 6.5 months in arm B, respectively. Conclusion: In our experience, combination of bevacizumab and chemotherapy had encouraging antitumor efficacy as first-line therapy in elderly patients with non-squamous NSCLC.

引用

页码：2457 / 2464

页数：8

共 23 条

[1] Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer A Systematic Review [J].

Behera, Madhusmita ;

Pillai, Rathi N. ;

Owonikoko, Taofeek K. ;

Kim, Sungjin ;

Steuer, Conor ;

Chen, Zhengjia ;

Saba, Nabil F. ;

Belani, Chandra P. ;

Khuri, Fadlo R. ;

Ramalingam, Suresh S. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) :1142-1147

[2] NCCTG N0821 (Alliance) A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer With Good Performance Status [J].

Dy, Grace K. ;

Molina, Julian R. ;

Qi, Yingwei ;

Ansari, Rafat ;

Thomas, Sachdev ;

Ross, Helen J. ;

Soori, Gamini ;

Anderson, Daniel ;

Aubry, Marie Christine ;

Meyers, Jeffrey ;

Adjei, Araba A. ;

Mandrekar, Sumithra ;

Adjei, Alex A. .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (08) :1146-1153

[3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[4] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Dikshit, Rajesh ;

Eser, Sultan ;

Mathers, Colin ;

Rebelo, Marise ;

Parkin, Donald Maxwell ;

Forman, David ;

Bray, Freddie .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386

[5] Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial [J].

Gridelli, C ;

Perrone, F ;

Gallo, C ;

Cigolari, S ;

Rossi, A ;

Piantedosi, F ;

Barbera, S ;

Ferraù, F ;

Piazza, E ;

Rosetti, F ;

Clerici, M ;

Bertetto, O ;

Robbiati, SF ;

Frontini, L ;

Sacco, C ;

Castiglione, F ;

Favaretto, A ;

Novello, S ;

Migliorino, MR ;

Gasparini, G ;

Galetta, D ;

Iaffaioli, RV ;

Gebbia, V .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) :362-372

[6] Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small-cell lung cancer: The MILES-2P studies [J].

Gridelli, Cesare ;

Maione, Paolo ;

Illiano, Alfonso ;

Piantedosi, Franco Vito ;

Favaretto, Adolfo ;

Bearz, Alessandra ;

Robbiati, Sergio Federico ;

Filipazzi, Virginio ;

Lorusso, Vito ;

Carrozza, Francesco ;

Iaffaioli, Rosario Vincenzo ;

Manzione, Luigi ;

Gallo, Ciro ;

Morabito, Alessandro ;

Perrone, Francesco .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) :4663-4669

[7] Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology [J].

Gridelli, Cesare ;

Balducci, Lodovico ;

Ciardiello, Fortunato ;

Di Maio, Massimo ;

Felip, Enriqueta ;

Langer, Corey ;

Lilenbaum, Rogerio C. ;

Perrone, Francesco ;

Senan, Suresh ;

de Marinis, Filippo .

CLINICAL LUNG CANCER, 2015, 16 (05) :325-333

[8] Treatment of advanced non-small-cell lung cancer in the elderly [J].

Gridelli, Cesare ;

Maione, Paolo ;

Rossi, Antonio ;

Ferrara, Marianna Luciana ;

Castaldo, Vincenzo ;

Palazzolo, Giovanni ;

Mazzeo, Nicole .

LUNG CANCER, 2009, 66 (03) :282-286

[9] Bevacizumab: A Review of Its Use in Advanced Cancer [J].

Keating, Gillian M. .

DRUGS, 2014, 74 (16) :1891-1925

[10] Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer Secondary Analyses of the ECOG 4599 and PointBreak Trials [J].

Langer, Corey J. ;

Socinski, Mark A. ;

Patel, Jyoti D. ;

Sandler, Alan B. ;

Schiller, Joan H. ;

Leon, Larry ;

Hazard, Sebastien J. ;

Ramalingam, Suresh S. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (05) :441-447

← 1 2 3 →